158 related articles for article (PubMed ID: 16184369)
1. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography.
Orlefors H; Sundin A; Lu L; Oberg K; Långström B; Eriksson B; Bergström M
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):60-5. PubMed ID: 16184369
[TBL] [Abstract][Full Text] [Related]
2. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
[TBL] [Abstract][Full Text] [Related]
3. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center.
Nikolaou A; Thomas D; Kampanellou C; Alexandraki K; Andersson LG; Sundin A; Kaltsas G
J Endocrinol Invest; 2010 Dec; 33(11):794-9. PubMed ID: 20332708
[TBL] [Abstract][Full Text] [Related]
4. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
Eriksson B; Bergström M; Lilja A; Ahlström H; Långström B; Oberg K
Acta Oncol; 1993; 32(2):189-96. PubMed ID: 7686763
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography.
Sundin A; Eriksson B; Bergström M; Bjurling P; Lindner KJ; Oberg K; Långström B
Nucl Med Biol; 2000 Jan; 27(1):33-41. PubMed ID: 10755643
[TBL] [Abstract][Full Text] [Related]
7. 11C-5-hydroxytryptophan positron emission tomography after radiofrequency ablation of neuroendocrine tumor liver metastases.
Norlén O; Nilsson A; Krause J; Stålberg P; Hellman P; Sundin A
Nucl Med Biol; 2012 Aug; 39(6):883-90. PubMed ID: 22381780
[TBL] [Abstract][Full Text] [Related]
8. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies.
Eriksson B; Bergström M; Orlefors H; Sundin A; Oberg K; Långström B
Q J Nucl Med; 2000 Mar; 44(1):68-76. PubMed ID: 10932603
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors.
Orlefors H; Sundin A; Ahlström H; Bjurling P; Bergström M; Lilja A; Långström B; Oberg K; Eriksson B
J Clin Oncol; 1998 Jul; 16(7):2534-41. PubMed ID: 9667275
[TBL] [Abstract][Full Text] [Related]
10. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.
Timmers HJ; Hadi M; Carrasquillo JA; Chen CC; Martiniova L; Whatley M; Ling A; Eisenhofer G; Adams KT; Pacak K
J Nucl Med; 2007 Oct; 48(10):1599-606. PubMed ID: 17873132
[TBL] [Abstract][Full Text] [Related]
11. Nuclear imaging of neuroendocrine tumours.
Sundin A; Garske U; Orlefors H
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
[TBL] [Abstract][Full Text] [Related]
12. [(11)C]5-HTP and microPET are not suitable for pharmacodynamic studies in the rodent brain.
Visser AK; Ramakrishnan NK; Willemsen AT; Di Gialleonardo V; de Vries EF; Kema IP; Dierckx RA; van Waarde A
J Cereb Blood Flow Metab; 2014 Jan; 34(1):118-25. PubMed ID: 24084697
[TBL] [Abstract][Full Text] [Related]
13. The role of PET in localization of neuroendocrine and adrenocortical tumors.
Eriksson B; Bergström M; Sundin A; Juhlin C; Orlefors H; Oberg K; Långström B
Ann N Y Acad Sci; 2002 Sep; 970():159-69. PubMed ID: 12381551
[TBL] [Abstract][Full Text] [Related]
14. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
Orlefors H; Sundin A; Garske U; Juhlin C; Oberg K; Skogseid B; Langstrom B; Bergstrom M; Eriksson B
J Clin Endocrinol Metab; 2005 Jun; 90(6):3392-400. PubMed ID: 15755858
[TBL] [Abstract][Full Text] [Related]
15. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
Koopmans KP; de Vries EG; Kema IP; Elsinga PH; Neels OC; Sluiter WJ; van der Horst-Schrivers AN; Jager PL
Lancet Oncol; 2006 Sep; 7(9):728-34. PubMed ID: 16945767
[TBL] [Abstract][Full Text] [Related]
16. PET in the diagnosis of neuroendocrine tumors.
Sundin A; Eriksson B; Bergström M; Långström B; Oberg K; Orlefors H
Ann N Y Acad Sci; 2004 Apr; 1014():246-57. PubMed ID: 15153441
[TBL] [Abstract][Full Text] [Related]
17. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours.
Krüger S; Buck AK; Blumstein NM; Pauls S; Schelzig H; Kropf C; Schumann C; Mottaghy FM; Hombach V; Reske SN
J Intern Med; 2006 Dec; 260(6):545-50. PubMed ID: 17116005
[TBL] [Abstract][Full Text] [Related]
18. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
Junik R; Drobik P; Małkowski B; Kobus-Błachnio K
Adv Med Sci; 2006; 51():66-8. PubMed ID: 17357280
[TBL] [Abstract][Full Text] [Related]
19. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
20. Positron-emission tomography as a radiological technique in neuroendocrine gastrointestinal tumors.
Eriksson B; Lilja A; Ahlström H; Bjurling P; Bergström M; Lindner KJ; Långström B; Oberg K
Ann N Y Acad Sci; 1994 Sep; 733():446-52. PubMed ID: 7978893
[No Abstract] [Full Text] [Related]
[Next] [New Search]